Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 5 | BMC Immunology

Figure 5

From: DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice

Figure 5

Therapeutic efficacy of scFvNLDC-145-HER2 vaccine. A BALB/c mice (10 mice per group) were inoculated s.c. with D2F2/E2 tumor cells. On day 7, animals with tumors sizing ~ 40 mm3 were immunized with scFvNLDC-145-HER2 or respective controls. Treatment was repeated on day 21. Tumor developments were monitored, and animal survival was calculated. Left panel, kinetics of tumor growth; Right panel, survival curve. The data were represented as the mean tumor volume (mm3) and representative of two experiments with comparable results. **, P < 0.01, scFvNLDC-145-HER2 compared with other groups. B temporary depletion of CD4+ Foxp3+ regulatory T cells by a single injection of low-dose CTX. BALB/c mice (3 mice per group) were inoculated s.c. with D2F2/E2 tumor cells. When the tumors were 3-4 mm in diameter (day 7), mice were injected i.p. with CTX (CTX injected) or PBS (Tumor bearing). Naive mice (Untreated) were used as control. The spleens were harvested at different time points and analyzed for the regulatory T cells. Left panel, Percentage of CD4+ Foxp3+ in total CD4+ cells; Right panel, a representative dot plot. Bars, SE. *, P < 0.05, CTX group compared with other groups. C BALB/c mice (10 mice per group) were inoculated s.c. with D2F2/E2 tumor cells. When the tumors were 3-4 mm in diameter (day 7), mice received CTX injection. Four days later (day 11), animals were vaccinated with various DNA vaccines. Treatment was repeated after two weeks. Left panel, kinetics of tumor growth; Right panel, survival curve. The data were represented as the mean tumor volume (mm3) and representative of two experiments with comparable results. **, P < 0.01, scFvNLDC-145-HER2/CTX compared with other groups.

Back to article page